Typical antipsychotics vs Atypical antipsychotics
How to tell Typical antipsychotics and Atypical antipsychotics apart when a board question makes them look alike.
Typical means more EPS/prolactin from strong D2 blockade; atypical means more metabolic risk with serotonin-D2 profile.
Side by side
Haloperidol/fluphenazine pattern with stronger D2 blockade, extrapyramidal symptoms, hyperprolactinemia, and neuroleptic malignant syndrome risk.
Olanzapine/clozapine/risperidone pattern with more serotonin activity, lower EPS tendency overall, and metabolic syndrome risk.
First-generation antipsychotics primarily block dopamine D2 receptors in mesolimbic and nigrostriatal pathways.
Second-generation antipsychotics combine D2 antagonism with serotonin receptor effects and broader receptor profiles.
Acute dystonia, parkinsonism, akathisia, or tardive dyskinesia after haloperidol supports typical antipsychotic toxicity.
Weight gain, dyslipidemia, hyperglycemia, clozapine agranulocytosis, or myocarditis points atypical antipsychotic risk.
The trap
Both can cause neuroleptic malignant syndrome and both block dopamine, so the deciding axis is the receptor profile and side-effect signature. TYPICAL antipsychotics (haloperidol, fluphenazine, chlorpromazine, thioridazine) are potent D2 antagonists; high-potency typicals (haloperidol, fluphenazine) cause more EXTRAPYRAMIDAL symptoms (acute dystonia in hours to days, akathisia in days to weeks, parkinsonism in weeks to months, tardive dyskinesia in months to years), hyperprolactinemia (galactorrhea, gynecomastia, amenorrhea), and NMS; low-potency typicals (chlorpromazine, thioridazine) cause more ANTICHOLINERGIC, ANTI-HISTAMINE (sedation, weight gain), and ANTI-ADRENERGIC (orthostatic hypotension) effects. ATYPICAL antipsychotics (risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, clozapine) have serotonin 5-HT2A plus D2 antagonism with lower EPS risk and lower prolactin elevation but more METABOLIC syndrome (weight gain, diabetes, dyslipidemia, especially with olanzapine and clozapine). Clozapine is reserved for refractory schizophrenia and reduces suicidality; high-yield toxicities are AGRANULOCYTOSIS (weekly CBC monitoring), MYOCARDITIS, SEIZURES, and severe metabolic syndrome.
The repair move
For antipsychotics, separate movement/prolactin toxicity from metabolic and clozapine-specific toxicity.
Try a free question
CoreA patient receives haloperidol and develops acute dystonia and parkinsonism from strong dopamine D2 blockade. Which antipsychotic group best fits?
Show answer and explanation
Answer: A. Typical antipsychotic. Typical antipsychotics are strong D2 blockers and have higher extrapyramidal symptom risk.
Why the other choices are tempting
- B. Atypical antipsychotics generally have more serotonin activity and lower EPS risk than high-potency typical drugs.
- C. SSRIs treat depression/anxiety and do not strongly block D2 receptors.
- D. Mood stabilizers do not produce the classic high-potency D2 EPS pattern.
- E. Benzodiazepines enhance GABA-A signaling and do not cause D2 blockade.
Flashcards
Tap a card to flip it.
What is the fastest separator for Typical antipsychotics vs Atypical antipsychotics?
Typical means more EPS/prolactin from strong D2 blockade; atypical means more metabolic risk with serotonin-D2 profile.
What clue should make you choose Typical antipsychotics?
Haloperidol/fluphenazine pattern with stronger D2 blockade, extrapyramidal symptoms, hyperprolactinemia, and neuroleptic malignant syndrome risk.
Quick answers
What is the fastest way to tell Typical antipsychotics from Atypical antipsychotics?
Typical means more EPS/prolactin from strong D2 blockade; atypical means more metabolic risk with serotonin-D2 profile.
What is the key clue for Typical antipsychotics?
Haloperidol/fluphenazine pattern with stronger D2 blockade, extrapyramidal symptoms, hyperprolactinemia, and neuroleptic malignant syndrome risk.
What is the key clue for Atypical antipsychotics?
Olanzapine/clozapine/risperidone pattern with more serotonin activity, lower EPS tendency overall, and metabolic syndrome risk.
What is the common trap with Typical antipsychotics vs Atypical antipsychotics?
Both can cause neuroleptic malignant syndrome and both block dopamine, so the deciding axis is the receptor profile and side-effect signature. TYPICAL antipsychotics (haloperidol, fluphenazine, chlorpromazine, thioridazine) are potent D2 antagonists; high-potency typicals (haloperidol, fluphenazine) cause more EXTRAPYRAMIDAL symptoms (acute dystonia in hours to days, akathisia in days to weeks, parkinsonism in weeks to months, tardive dyskinesia in months to years), hyperprolactinemia (galactorrhea, gynecomastia, amenorrhea), and NMS; low-potency typicals (chlorpromazine, thioridazine) cause more ANTICHOLINERGIC, ANTI-HISTAMINE (sedation, weight gain), and ANTI-ADRENERGIC (orthostatic hypotension) effects. ATYPICAL antipsychotics (risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, clozapine) have serotonin 5-HT2A plus D2 antagonism with lower EPS risk and lower prolactin elevation but more METABOLIC syndrome (weight gain, diabetes, dyslipidemia, especially with olanzapine and clozapine). Clozapine is reserved for refractory schizophrenia and reduces suicidality; high-yield toxicities are AGRANULOCYTOSIS (weekly CBC monitoring), MYOCARDITIS, SEIZURES, and severe metabolic syndrome.